title: Evolving molecular-based targeted therapy for cancer: an exciting field.
abstract: The development of molecular biology tools has led to the identification of numerous therapeutic targets in cancer cells. In this article, we discuss the rational and clinical data supporting the use of agents that selectively target epidermal and vascular endothelial growth factors in selected cancers.
authors.affiliation: Department of Medicine, Kellogg Cancer Care Center, Evanston Northwestern Healthcare, IL 60201, USA.
authors.forename: Benedito
authors.initials: B
authors.lastname: Carneiro
authors.forename: Katy
authors.initials: K
authors.lastname: Hsiao
authors.forename: Janardan
authors.initials: J
authors.lastname: Khandekar
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors